BioSpace News Archive

- Primary Endpoints Met in PSOARING 1 and PSOARING 2 Clinical Trials (P-values <0.0001) - - Up to 80% of Patients Achieved ≥1-Grade Improvement in PGA - - All Secondary Endpoints Achieved in Both Trials, Including PASI75 - - Tapinarof is a Potential First-in-Class Psoriasis Treatment with a Novel Mechanism of Action - - To Date, Over 2,200 Subjects Have Enrolled in 17 Clinical Trials of Tapinarof

AllStar Health Brands Inc. (OTC PINK:ALST) a specialty pharmaceutical and nutritional supplements company and TPT Global Tech a technology and solutions company are pleased to announce signing a Non Exclusive Distribution Agreement for Canada and US to add to the existing Non-Exclusive Distribution Agreement for Mexico and other Latin American countries.